MX2022013927A - Composiciones y metodos para tratar la epilepsia. - Google Patents

Composiciones y metodos para tratar la epilepsia.

Info

Publication number
MX2022013927A
MX2022013927A MX2022013927A MX2022013927A MX2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A
Authority
MX
Mexico
Prior art keywords
methods
treating epilepsy
compositions
administering
inhibitor
Prior art date
Application number
MX2022013927A
Other languages
English (en)
Inventor
Ted Yednock
Sethu Sankaranarayanan
Jeanne T Paz
Original Assignee
The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Glads
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Glads filed Critical The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Glads
Publication of MX2022013927A publication Critical patent/MX2022013927A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se refiere, en términos generales, a métodos para prevenir, reducir el riesgo de desarrollar o tratar la epilepsia, que comprenden administrar a un sujeto un inhibidor de la vía clásica del complemento.
MX2022013927A 2020-05-05 2021-05-05 Composiciones y metodos para tratar la epilepsia. MX2022013927A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063020245P 2020-05-05 2020-05-05
PCT/US2021/030930 WO2021242493A2 (en) 2020-05-05 2021-05-05 Compositions and methods for treating epilepsy

Publications (1)

Publication Number Publication Date
MX2022013927A true MX2022013927A (es) 2022-11-30

Family

ID=78745740

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013927A MX2022013927A (es) 2020-05-05 2021-05-05 Composiciones y metodos para tratar la epilepsia.

Country Status (8)

Country Link
US (1) US20240034775A1 (es)
EP (1) EP4146276A2 (es)
JP (1) JP2023524819A (es)
CN (1) CN115996752A (es)
AU (1) AU2021278819A1 (es)
CA (1) CA3177879A1 (es)
MX (1) MX2022013927A (es)
WO (1) WO2021242493A2 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014287221C1 (en) * 2013-07-09 2020-03-05 Annexon, Inc. Anti-complement factor C1q antibodies and uses thereof
CN107001473B (zh) * 2014-11-19 2021-07-09 豪夫迈·罗氏有限公司 抗-运铁蛋白受体抗体及使用方法

Also Published As

Publication number Publication date
WO2021242493A3 (en) 2022-06-09
AU2021278819A1 (en) 2022-11-24
JP2023524819A (ja) 2023-06-13
WO2021242493A2 (en) 2021-12-02
CA3177879A1 (en) 2021-12-02
CN115996752A (zh) 2023-04-21
EP4146276A2 (en) 2023-03-15
US20240034775A1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
MY196582A (en) PD-1/PD-L1 Inhibitors
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
MX2022007968A (es) Dosificacion de gamma-hidroxibutirato (ghb).
MX2022001004A (es) Inhibidores de enzimas.
NI202100018A (es) Moduladores de la expresión de pnpla3
JOP20210158A1 (ar) مُعَدِّلات التعبير الجيني عن hsd17b13
PH12019502174A1 (en) Modulators of pcsk9 expression
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
MX2020012497A (es) Moduladores de la expresion de apol1.
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
TN2019000156A1 (en) Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease
MX2022000812A (es) Metodos de tratamiento de hiperplasia suprarrenal congenita.
WO2023108110A3 (en) Combination therapy for treating abnormal cell growth
MX2021009535A (es) Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación.
MX2022000811A (es) Inhibidores de enzimas.
MX2022000545A (es) Inhibidores de enzimas.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
MX2022013927A (es) Composiciones y metodos para tratar la epilepsia.
MX2022010960A (es) Métodos y composiciones para tratar el trastorno por uso de cannabis y mitigar la abstinencia de cannabinoides.
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.
WO2020086954A3 (en) Treatments for charcot-marie-tooth disease
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
MX2022000801A (es) Composicion y metodo para prevenir, aliviar o tratar lesion del higado.
MX2022003720A (es) Un metodo para tratar los trastornos del estado de animo.
MX2021004819A (es) Composiciones y metodos para tratar lesiones cerebrales.